Last reviewed · How we verify
NCT04513028
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
NA trial testing Beta-Glucan in Melanoma Stage III in 30 participants. Currently enrolling.
31 July 2026
Quick facts
| Lead sponsor | Kelly McMasters |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 3 November 2020 |
| Primary completion | 31 July 2026 |
| Estimated completion | 15 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Beta-Glucan — full drug profile →
Conditions studied
- Melanoma Stage III — all drugs for Melanoma Stage III →
- Melanoma Stage IV — all drugs for Melanoma Stage IV →
Sponsor
Kelly McMasters
Who can join
18 and older, any sex, with Melanoma Stage III or Melanoma Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy.
Cotechini T, Atallah A, Grossman A. · · 2021 · cited 49× · PMID 33924237 · DOI 10.3390/cells10040960 -
From Cancer Therapy to Winemaking: The Molecular Structure and Applications of β-Glucans and β-1, 3-Glucanases.
Caseiro C, Dias JNR, de Andrade Fontes CMG, Bule P. · · 2022 · cited 40× · PMID 35328577 · DOI 10.3390/ijms23063156
Verify or expand the search:
- PubMed search for NCT04513028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Beta-Glucan
Trials testing the same drug.
- NCT03769012 — Ability of Beta-glucan Supplementation to Augment Immune Function · NA · completed
- NCT04710290 — A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers · Phase 2, PHASE3 · unknown
Other recruiting trials for Melanoma Stage III
Currently open trials in the same condition.
- NCT06204991 — To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma · Phase 1 · recruiting
- NCT06551064 — Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients · Phase 1 · active not recruiting
- NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
- NCT05655312 — MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma · Phase 1, PHASE2 · recruiting
- NCT05652673 — Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04513028 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kelly McMasters
- Last refreshed: 30 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04513028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing